Journal
SMALL
Volume 17, Issue 14, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202005993
Keywords
anti‐ PD‐ 1 antibody; immunogenic cell death (ICD); pancreatic cancer (PDAC); platinum drug; silicasome nanocarrier
Categories
Funding
- U.S. Public Health Service Grants [1U01CA198846, 1R01CA247666-01A1]
- NCNST
Ask authors/readers for more resources
This study developed a platform based on mesoporous silica nanoparticles for high-dose loading of activated platinum chemo agents, improving drug delivery efficiency. Encapsulation of activated oxaliplatin in lipid bilayer-coated silica nanoparticles demonstrated improved pharmacokinetics, intratumor delivery, cytotoxicity, and reduced bone marrow toxicity. Additionally, the nanoparticles induced features of immunogenic cell death and significantly extended the survival outcome in pancreatic cancer models.
In this study a mesoporous silica nanoparticle (MSNP) based platform is developed for high-dose loading of a range of activated platinum (Pt) chemo agents that can be attached to the porous interior through the use of electrostatic and coordination chemistry under weak-basic pH conditions. In addition to the design feature for improving drug delivery, the MSNP can also be encapsulated in a coated lipid bilayer (silicasome), to improve the colloidal stability after intravenous (IV) injection. Improved pharmacokinetics and intratumor delivery of encapsulated activated oxaliplatin (1,2-diamminocyclohexane platinum(II) (DACHPt)) over free drug in an orthotopic Kras-derived pancreatic cancer (PDAC) model is demonstrated. Not only does IV injection of the DACHPt silicasome provide more efficacious cytotoxic tumor cell killing, but can also demonstrate that chemotherapy-induced cell death is accompanied by the features of immunogenic cell death (ICD) as well as a dramatic reduction in bone marrow toxicity. The added ICD features are reflected by calreticulin and high-mobility group box 1 expression, along with increased CD8(+)/FoxP3(+) T-cell ratios and evidence of perforin and granzyme B release at the tumor site. Subsequent performance of a survival experiment, demonstrates that the DACHPt silicasome generates a significant improvement in survival outcome, which can be extended by delayed administration of the anti-PD-1 antibody.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available